Use the Back button in your browser to see the other results of your search or to select another record.
Cost-effectiveness of home versus clinic-based management of chronic heart failure: extended follow-up of a pragmatic, multicentre randomized trial cohort - the WHICH? study (Which Heart Failure Intervention Is Most Cost-Effective and Consumer Friendly in Reducing Hospital Care) |
Maru S, Byrnes J, Carrington MJ, Chan Y-K, Thompson DR, Stewart S, Scuffham PA, on behalf of the WHICH? Trial Investigators |
International Journal of Cardiology 2015 Dec 15;201:368-375 |
clinical trial |
5/10 [Eligibility criteria: No; Random allocation: Yes; Concealed allocation: No; Baseline comparability: Yes; Blind subjects: No; Blind therapists: No; Blind assessors: No; Adequate follow-up: Yes; Intention-to-treat analysis: No; Between-group comparisons: Yes; Point estimates and variability: Yes. Note: Eligibility criteria item does not contribute to total score] *This score has been confirmed* |
OBJECTIVE: To assess the long-term cost-effectiveness of two multidisciplinary management programs for elderly patients hospitalized with chronic heart failure (CHF) and how it is influenced by patient characteristics. METHODS: A trial-based analysis was conducted alongside a randomized controlled trial of 280 elderly patients with CHF discharged to home from three Australian tertiary hospitals. Two interventions were compared: home-based intervention (HBI) that involved home visiting with community-based care versus specialized clinic-based intervention (CBI). Bootstrapped incremental cost-utility ratios were computed based on quality-adjusted life-years (QALYs) and total healthcare costs. Cost-effectiveness acceptability curves were constructed based on incremental net monetary benefit (NMB). We performed multiple linear regression to explore which patient characteristics may impact patient-level NMB. RESULTS: During median follow-up of 3.2 years, HBI was associated with slightly higher QALYs (+0.26 years per person; p = 0.078) and lower total healthcare costs (AU$ -13,100 per person; p = 0.025) mainly driven by significantly reduced duration of all-cause hospital stay (-10 days; p = 0.006). At a willingness-to-pay threshold of AU$ 50,000 per additional QALY, the probability of HBI being better-valued was 96% and the incremental NMB of HBI was AU$ 24,342 (discounted, 5%). The variables associated with increased NMB were HBI (versus CBI), lower Charlson Comorbidity Index, no hyponatremia, fewer months of HF, fewer prior HF admissions < 1 year and a higher patient's self-care confidence. HBI's net benefit further increased in those with fewer comorbidities, a lower self-care confidence or no hyponatremia. CONCLUSIONS: Compared with CBI, HBI is likely to be cost-effective in elderly CHF patients with significant comorbidity.
|